GleamWall
中文EN

SKVI SKINVISIBLE, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1085277 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.8%
TTM net income YoY-111.2%
TTM EPS YoY—
Revenue 3-yr CAGR1.9%
Net income 3-yr CAGR—

Margins

Gross margin100.0%
Operating margin-2,193.7%
Net margin-4,898.2%
FCF margin—
EBITDA margin-2,097.8%

Returns

ROE—
ROA-829.6%
ROIC (approx.)—
Asset turnover0.17x

Leverage & solvency

Liabilities / assets9,592.8%
Debt / equity—
Current ratio0.01x
Interest coverage-0.81x

Cash quality & payout

Operating cash flow / net income0.08x
Accruals ratio-759.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$6,166$5,000$5,000$5,000$5,000$5,000$5,000$5,000
Gross profit$6,166$5,000$5,000$5,000$5,000$5,000$5,000$5,000
SG&A expense$112,378$112,821$125,931$114,051$105,939$136,174$139,912$198,693
Operating income-$111,396-$112,817-$125,938-$114,169-$106,057-$136,237-$139,852-$198,743
Interest expense$144,288$142,716$141,246$144,188$144,188$142,720$141,153$168,663
Net income-$255,684-$255,533-$267,184-$258,357-$250,245-$274,427-$281,005$314,771
EBITDA-$106,212-$107,821-$120,931-$109,051-$100,939-$131,174-$134,912-$193,693
EPS (diluted)————————
Balance sheet
Cash & equivalents$4,370$3,959$1,798$2,620$645$120$13,396$10,336
Receivables$5,000$5,000$5,000$5,000$5,000$5,000$470$5,000
Current assets$31,462$33,301$24,390$27,531$28,469$33,102$38,305$42,028
Intangibles$84,849$90,033$95,029$100,036$105,154$110,273$111,249$116,189
Total assets$116,311$123,334$119,419$127,567$133,623$143,375$149,554$158,217
Current liabilities$5.79M$5.54M$5.28M$5.02M$4.77M$4.53M$4.26M$3.66M
Total liabilities$11.16M$10.91M$10.65M$10.39M$10.14M$9.90M$9.63M$9.38M
Shareholders' equity-$11.04M-$10.79M-$10.53M-$10.26M-$10.00M-$9.75M-$9.48M-$9.22M
Shares outstanding5.40M5.40M5.40M5.40M5.40M5.40M5.40M5.32M
Cash flow statement
Operating cash flow-$90,490$2,161-$822$1,975$524-$9,189-$31,720-$16,912
Capital expenditure———$0-$1——$0
Free cash flow———$1,975$525——-$16,912
Investing cash flow———$0$1——$0
Financing cash flow———$0$0$0$34,780$26,636
Depreciation & amortization$5,184$4,996$5,007$5,118$5,118$5,063$4,940$5,050

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.